Growth Hormone Deficiency Clinical Trial
— GHATOfficial title:
The Effect of a Long-Term Growth Hormone Supplementation on the Whole-Body Metabolic Characteristics and Adipose Tissue Phenotype in Growth Hormone Deficient Adults: the 5-yr Follow-up
Verified date | April 2018 |
Source | Slovak Academy of Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is designed as a follow up study to that performed in 2005.
In the Baseline study (2005) extensive clinical whole body metabolic phenotyping was combined
with in depth molecular and cellular biology analyses aimed at investigating the adipose
tissue morphology as well as metabolic and inflammatory phenotypes in the adult GHD patients.
Results published in (Ukropec et al., 2008)
In this study identical endpoints will be investigated with the same methodology and within
the same population; in order to seek relevant answers to questions on how the 6-yrs of rhGH
therapy affects the
- whole body insulin sensitivity
- energy expenditure
- body fat distribution
- hepatic and skeletal muscle lipid content;
as well as how it influences the adipose tissue
- endocrine,
- metabolic &
- inflammatory phenotypes.
The strength of the planned study lies in the extensive whole body and adipose tissue
phenotyping before and after the 6-year rhGH replacement therapy, that allows to determine
the long-term effects of rhGH replacement therapy in GHD adults.
Envisaged weakness is the limited size of the population; GHD adults (n=20); controls [age
BMI and gender matched] (n=20). This, however, reflects [is limited by] the complexity of the
study protocol as well as the stringency of the inclusion criteria.
The clinical data obtained by methods of - integrated physiology would provide an excellent
interpretation background for molecular-genetic studies at the tissue (adipose tissue) and
cellular (adipocytes) level. Integration of the two could bring a new quality in the
investigators understanding of metabolic derangements present in GHD, and will allow
extending the investigators knowledge on the mechanisms of the long-term rhGH-therapy-induced
improvement on body composition, metabolic health and the cardiovascular risk.
Status | Completed |
Enrollment | 44 |
Est. completion date | August 2015 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 50 Years |
Eligibility |
Inclusion Criteria: We will follow inclusion-exclusion criteria which are very much like those used in the pilot study performed in 2005. - Briefly, duration of the GHD prior to entering the study should last for at least 3 years prior rhGH treatment starts. Age of individuals eligible to enter should be 20-50 years old. All patients and healthy control volunteers will provide the witnessed written informed consent before entry into the study. - It has to be noted that differences in the etiology of GHD might influence several of the outcomes we plan to measure. Presence or absence of possible bias should therefore be excluded for each specific outcome prior further statistical data analysis. Individuals with different degree of pituitary deficiency will therefore be eligible to enter the study. - Complex information on the adequacy of the hormone replacement therapy will be based on the serum levels of growth hormone, insulin-like growth factor 1, free thyroid hormone, testosterone/estradiol, urinary free cortisol FT4, and morning cortisol. Examination and laboratory testing relevant to this study will be performed within 6 months of entering the study. The 24-hour urinary free cortisol will only be determined in individuals hospitalized in a period of two month prior to the study entry. Exclusion Criteria: - None of the patients should receive lipid lowering treatment. Patients with malignant disease, diabetes mellitus, existing vascular disease and uncontrolled hypertension are not eligible to enter this study. |
Country | Name | City | State |
---|---|---|---|
Slovakia | Inst. Exp. Endocrinology Slovak Acad Sci | Bratislava | |
Slovakia | V th Internal Clinic, Univeristy Hospital Bratislava, Comenius University | Bratislava | |
Slovakia | National Institute of Endocrinology and Diabetology | Lubochna |
Lead Sponsor | Collaborator |
---|---|
Slovak Academy of Sciences | PFIZER, Bratislava, Slovakia |
Slovakia,
Ukropec J, Penesová A, Skopková M, Pura M, Vlcek M, Rádiková Z, Imrich R, Ukropcová B, Tajtáková M, Koska J, Zórad S, Belan V, Vanuga P, Payer J, Eckel J, Klimes I, Gasperíková D. Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J Clin Endocrinol Metab. 2008 Jun;93(6):2255-62. doi: 10.1210/jc.2007-2188. Epub 2008 Mar 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effects of GH therapy to GHD adults - the whole body level | to determine the effects of a long-term (6 years) growth hormone supplementation on the whole-body metabolic phenotype in adult GHD patients (namely (i) insulin sensitivity, (ii) energy expenditure, (iii) body fat distribution and (iv) bone mineral density, (v) glucose tolerance, (vi) hepatic and skeletal muscle lipid content as well as (vii) serum lipids and (viii) inflammatory markers in circulation. | 12 months | |
Primary | GH therapy effects on the endocrine, metabolic & inflammatory properties of adipose tissue | to investigate the effects of long-term (5 years) growth hormone supplementation on the subcutaneous adipose tissue (i) endocrine, (ii) metabolic and (iii) inflammatory phenotype in adult GHD patients, by extensive profiling of adipose tissue protein & gene expression (protein antibody arrays & real-time PCR) which could identify potential molecular mechanisms associated with abdominal obesity and insulin resistance modulated by rhGH replacement therapy. | 2 years | |
Secondary | comparison of GHD & control population | to compare the whole-body metabolic profile and subcutaneous adipose tissue phenotype of rhGH supplemented GHD adults with that of the healthy control group | 2 years | |
Secondary | Identification of the adiposity-associated parameters | to evaluate parameters associated primarily with adiposity which are largely independent on the severity of the GH deficiency | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02243852 -
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
|
N/A | |
Completed |
NCT01440686 -
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT00990340 -
Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method
|
Phase 4 | |
Completed |
NCT00235599 -
The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children.
|
N/A | |
Completed |
NCT00149708 -
Consequence of Lifetime Isolated Growth Hormone Deficiency
|
N/A | |
Completed |
NCT00459940 -
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
|
N/A | |
Completed |
NCT01157793 -
A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood
|
Phase 4 | |
Completed |
NCT00004365 -
Study of Pituitary Size and Function in Familial Dwarfism of Sindh
|
N/A | |
Recruiting |
NCT00227253 -
Chromosome 18 Clinical Research Center
|
||
Recruiting |
NCT04121780 -
Growth Hormone Replacement Therapy for Retried Professional Football Players
|
Phase 2 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT01090778 -
Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
|
Phase 2 | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT01062529 -
Peripheral Metabolic Effects of Somatostatin
|
N/A | |
Completed |
NCT00616278 -
National Cooperative Growth Study in CKD
|
N/A | |
Completed |
NCT02693522 -
Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency
|
Phase 3 | |
Recruiting |
NCT02908958 -
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
|
Phase 4 | |
Terminated |
NCT01243892 -
A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device
|
N/A | |
Withdrawn |
NCT00638287 -
Inter-Assay Growth Hormone and IGF-I Variability
|
N/A | |
Completed |
NCT00929799 -
Growth Hormone and Glucose Metabolism
|
Phase 4 |